I-Rhabdomyosarcoma

I-Rhabdomyosarcoma iyisimila somdlavuza (esibi) semisipha enamathele emathanjeni. Lo mdlavuza uhlasela kakhulu izingane.

I-Rhabdomyosarcoma ingenzeka ezindaweni eziningi emzimbeni. Izindawo ezivame kakhulu ikhanda noma intamo, uhlelo lokuchama noma lokuzala, kanye nezingalo noma imilenze.

Imbangela ye-rhabdomyosarcoma ayaziwa. Kuyisigaxa esingavamile esinamacala amasha amasha angamakhulu ambalwa ngonyaka e-United States.

Ezinye izingane ezinokukhubazeka okuthile kokuzalwa zisengozini eyengeziwe. Eminye imindeni inokuguqulwa kwezakhi zofuzo okwandisa le ngozi. Iningi lezingane ezine-rhabdomyosarcoma azinazo izinto eziyingozi ezaziwayo.

Uphawu oluvame kakhulu isisindo esingaba buhlungu noma singabi buhlungu.

Ezinye izimpawu ziyahlukahluka kuye ngendawo yesimila.

• Izicubu emakhaleni noma emphinjeni zingadala ukopha, ukuminyana, izinkinga zokugwinya, noma izinkinga zesistimu yezinzwa uma zingena ebuchosheni.
• Izimila ezizungeze amehlo zingadala ukuqhuma kweso, izinkinga ngombono, ukuvuvukala ezungeze iso, noma ubuhlungu.
• Izimila ezindlebeni, zingadala ubuhlungu, ukungezwa, noma ukuvuvukala.
• Isimila nezicubu zangasese kungadala inkathazo ukuqala ukuchama noma ukunyakaza kwamathumbu, noma ukungalawulwa kahle komchamo.
• Izicubu zemisipha zingaholela esigaxeni esibuhlungu, futhi zingaphutha ngokulimala.

Ukuxilongwa kuvame ukubambezeleka ngoba azikho izimpawu nangenxa yokuthi isimila singavela ngasikhathi sinye njengokulimala kwakamuva. Ukuxilongwa kusenesikhathi kubalulekile ngoba lo mdlavuza usakazeka ngokushesha.

Umhlinzeki wezokunakekelwa kwempilo uzokwenza ukuhlolwa komzimba. Imibuzo eningiliziwe izobuzwa mayelana nezimpawu nomlando wezokwelapha.

Izivivinyo ezinga-odwa zifaka:

• I-x-ray yesifuba
• I-CT scan esifubeni ukubheka ukusabalala kwesimila
• Ukuhlolwa kwe-CT kwesiza sesimila
• I-bone marrow biopsy (ingakhombisa ukuthi umdlavuza ususakazekile)
• Ukuskena kwamathambo ukufuna ukusabalala kwesimila
• Ukuskena kwe-MRI kwendawo yesimila
• Thepha umgogodla (ukubhoboza i-lumbar)

Ukwelashwa kuya ngesiza nohlobo lwe-rhabdomyosarcoma.

Kungaba yimisebe noma i-chemotherapy, noma kokubili, kuzosetshenziswa ngaphambi noma ngemuva kokuhlinzwa. Ngokuvamile, ukuhlinzwa nokwelashwa ngemisebe kusetshenziselwa ukwelapha indawo eyinhloko yesimila. I-Chemotherapy isetshenziselwa ukwelapha izifo kuzo zonke izingosi emzimbeni.

I-Chemotherapy yingxenye ebalulekile yokwelashwa ukuvimbela ukusabalala nokuphindeka komdlavuza. Izidakamizwa eziningi ezahlukahlukene zamakhemikhali ziyasebenza ukulwa ne-rhabdomyosarcoma. Umhlinzeki wakho uzoxoxa nawe ngalokhu.

Ingcindezi yokugula ingancishiswa ngokujoyina iqembu elisekela umdlavuza. Ukwabelana nabanye abanokuhlangenwe nakho okuvamile nezinkinga kungakusiza ungazizwa uwedwa.

Ngokwelashwa okunamandla, izingane eziningi ezine-rhabdomyosarcoma ziyakwazi ukuphila isikhathi eside. Ukwelashwa kuncike ohlotsheni oluthile lwesimila, lapho likhona nokuthi selusabalale kangakanani.

Izinkinga zalo mdlavuza noma ukwelashwa kwawo zifaka:

• Izinkinga ezivela ekhemotherapy
• Indawo lapho ukuhlinzwa kungenzeki khona
• Ukusabalala komdlavuza (i-metastasis)

Shayela umhlinzeki wakho uma ingane yakho inezimpawu ze-rhabdomyosarcoma.

Umdlavuza wezicubu ezithambile - i-rhabdomyosarcoma; I-sarcoma yezicubu ezithambile; I-Alveolar rhabdomyosarcoma; I-rhabdomyosarcoma embryonal; I-Sarcoma botryoides

UDome JS, uRodriguez-Galindo C, uSpunt SL, uSantana VM. Izimila eziqinile zezingane. Ku: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, abahleli. I-Abeloff’s Clinical Oncology. Umhlaka 6. IPhiladelphia, PA: Elsevier; 2020: isahluko 92.

IGoldblum JR, i-Folpe AL, i-Weiss SW. I-Rhabdomyosarcoma. Ku: Goldblum JR, Folpe AL, Weiss SW, ama-eds. Izicubu ze-Enzinger ne-Weiss's Tissue Tumors. Umhla wesi-7. IPhiladelphia, PA: Elsevier; 2020: isahluko 19.

Iwebhusayithi yeNational Cancer Institute. Ukwelashwa kwenguqulo yezempilo ye-rhabdomyosarcoma (PDQ) yezempilo. www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq. Kubuyekezwe uMeyi 7, 2020. Kufinyelelwe ngoJulayi 23, 2020.